|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Acutus Medical, Inc. (AFIB) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
27,850,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Acutus Medical is an arrhythmia management company. Co. designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Co.'s product portfolio includes access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters (available only in its European markets), mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Co.'s primary product is its AcQMap imaging and mapping system, which provides a paradigm-shifting approach to mapping the drivers and maintainers of arrhythmias with unmatched speed and precision.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
60,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$34,800 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Roman David |
Chief Financial Officer |
• – – |
2022-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
183,355 |
|
- |
|
| Roman David |
Chief Financial Officer |
• – – |
2022-04-01 |
4 |
D |
$1.30 |
$4,222 |
D/D |
(3,248) |
83,355 |
|
- |
|
| Mcquillan Steven |
SVP, Clinical Affairs & QA |
• – – |
2022-04-01 |
4 |
D |
$1.30 |
$953 |
D/D |
(733) |
45,844 |
|
- |
|
| Burgess Vincent J |
Chief Executive Officer |
• • – |
2022-04-01 |
4 |
D |
$1.30 |
$5,065 |
D/D |
(3,896) |
61,469 |
|
- |
|
| Mcquillan Steven |
SVP, Clinical Affairs & QA |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,000 |
46,577 |
|
- |
|
| Roman David |
Chief Financial Officer |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
86,603 |
|
- |
|
| Hinrichs James F. |
Director |
– • – |
2021-11-15 |
4 |
B |
$3.78 |
$151,220 |
D/D |
40,000 |
52,911 |
2.39 |
- |
|
| Pellegrini Niamh Louise |
Director |
– • – |
2021-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
4,172 |
4,172 |
|
- |
|
| Burgess Vincent J |
Chief Executive Officer |
• • – |
2021-08-05 |
4 |
D |
$15.52 |
$29,829 |
D/D |
(1,922) |
65,365 |
|
- |
|
| Mcquillan Steven |
SVP, Clinical Affairs & QA |
• – – |
2021-08-05 |
4 |
D |
$15.52 |
$4,734 |
D/D |
(305) |
14,577 |
|
- |
|
| Bonita David P |
Director |
– • • |
2021-07-19 |
4 |
B |
$14.00 |
$14,999,992 |
I/I |
1,071,428 |
1,677,361 |
2.25 |
- |
|
| Deerfield Partners, Lp |
Director by Deputization |
– • • |
2021-07-19 |
4 |
B |
$14.00 |
$14,999,992 |
I/I |
1,071,428 |
3,438,589 |
2.25 |
- |
|
| Orbimed Rof Ii Llc |
Director |
– • • |
2021-07-19 |
4 |
B |
$14.00 |
$14,999,992 |
I/I |
1,071,428 |
1,677,361 |
2.25 |
- |
|
| Deerfield Management Co /ny |
Director by Deputization |
– • • |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
I/I |
1,800 |
4,022 |
|
- |
|
| Elbardissi Andrew |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,800 |
4,022 |
|
- |
|
| Hinrichs James F. |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,800 |
12,911 |
|
- |
|
| Marzouk Shaden |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,800 |
4,022 |
|
- |
|
| Bonita David P |
Director |
– • • |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,800 |
4,022 |
|
- |
|
| Malik Shahzad |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,800 |
4,022 |
|
- |
|
| Roman David |
Chief Financial Officer |
• – – |
2021-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
36,603 |
36,603 |
|
- |
|
| Mcquillan Steven |
SVP, Clinical Affairs & QA |
• – – |
2021-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,882 |
14,882 |
|
- |
|
| Burgess Vincent J |
Chief Executive Officer |
• • – |
2021-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
45,065 |
67,287 |
|
- |
|
| Sheridan John F |
Director |
– • – |
2021-03-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,400 |
|
- |
|
| Sheridan John F |
Director |
– • – |
2021-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,147 |
7,547 |
|
- |
|
| Mcquillan Steven |
SVP, Clinical Affairs & QAOffi |
• – – |
2021-02-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,000 |
|
- |
|
97 Records found
|
|
Page 3 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
